MedicarePartD.guide

A non-government resource built from CMS public data

HIV treatment and prevention on every 2026 Delaware Part D plan

Pick a drug class, or type the drugs you want to check, and see which of the 10 stand-alone Part D plans in Delaware cover each one, on what tier, and with what restrictions.

A class overrides typed names. Separate names with commas; brand or generic both work.

  • Covered
  • Covered, needs prior authorization (PA) or step therapy (ST)
  • Not on the formulary
  • QL 60/30d = quantity limit, 60 units per 30 days
HIV treatment and prevention by 2026 Delaware Part D plan
DrugHumana Basic Rx Plan$0.00/moS5884-103Humana Value Rx Plan$4.30/moS5884-184Wellcare Value Script$5.60/moS4802-140Wellcare Classic$5.70/moS4802-079HealthSpring Assurance Rx$32.60/moS5617-214AARP Medicare Rx Saver from UHC$37.80/moS5921-350HealthSpring Extra Rx$66.60/moS5617-355AARP Medicare Rx Preferred from UHC$94.50/moS5921-387SilverScript Choice$97.40/moS5601-010Humana Premier Rx Plan$108.60/moS5884-151
Biktarvybictegravir/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Dovatodolutegravir and lamivudineTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Triumeqabacavir/dolutegravir/lamivudineTier 433%QL 180/30dTier 433%QL 180/30dTier 440%Tier 431%Tier 430%QL 300/30dTier 436%QL 180/30dTier 432%QL 300/30dTier 434%QL 180/30dTier 433%Tier 450%QL 180/30d
Genvoyaelvitegravir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Odefseyemtricitabine/rilpivirine/tenofovir alafenamideTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Symtuzadarunavir/cobicistat/emtricitabine/tenofovir alafenamideTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Julucadolutegravir and rilpivirineTier 525%QL 30/30dTier 526%QL 30/30dTier 525%Tier 525%Tier 525%Tier 525%QL 30/30dTier 525%Tier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Descovyemtricitabine and tenofovir alafenamideTier 525%QL 30/30dTier 526%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 525%QL 30/30dTier 531%QL 30/30dTier 525%Tier 533%QL 30/30d
Truvadaemtricitabine and tenofovir disoproxilNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot coveredNot covered
emtricitabine-tenofovirgeneric TruvadaTier 433%QL 30/30dTier 433%QL 30/30dTier 440%QL 30/30dTier 431%QL 30/30dTier 430%QL 30/30dTier 436%QL 30/30dTier 432%QL 30/30dTier 434%QL 30/30dTier 433%QL 30/30dTier 450%QL 30/30d
TivicaydolutegravirTier 525%QL 60/30dTier 526%QL 60/30dTier 525%Tier 525%Tier 430%QL 180/30dTier 525%QL 60/30dTier 432%QL 180/30dTier 531%QL 60/30dTier 525%Tier 533%QL 60/30d

Where a plan covers several strengths or forms of a drug, the cell shows the least restricted one. Costs are the 30-day preferred-pharmacy cost-sharing in the initial coverage phase, from the CMS 2026 formulary files. Click a plan for its full drug list.